by Portfolio Grader | October 3, 2012 10:00 am
The grades of five Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Threshold Pharmaceuticals (NASDAQ:THLD) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Threshold Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. In Portfolio Grader’s specific subcategory of Earnings Revisions, THLD also gets an A. For more information, get Portfolio Grader’s complete analysis of THLD stock.
NPS Pharmaceuticals (NASDAQ:NPSP) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The stock price has risen 22.3% over the past month, better than the 1.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NPSP stock.
This is a strong week for Maxygen (NASDAQ:MAXY). The company’s rating climbs to B from the previous week’s C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock has a trailing PE Ratio of 3.4. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
Celsion (NASDAQ:CLSN) gets a higher grade this week, advancing from a B last week to an A. Celsion is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. For more information, get Portfolio Grader’s complete analysis of CLSN stock.
Allos Therapeutics (NASDAQ:ALTH) earns a B this week, jumping up from last week’s grade of C. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. For more information, get Portfolio Grader’s complete analysis of ALTH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/10/5-biotechnology-stocks-to-buy-now-thld-npsp-maxy/
Short URL: http://investorplace.com/?p=240129
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.